Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

The Board of Directors, in a meeting held on 25 March 2025, declared an interim dividend of Rs 25 per equity share on a face ...

We recently compiled a list of the 10 Stocks with Potential to Rise 1000 Percent. In this article, we are going to take a ...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its ...

Diabetes continues to be a strong driver of sales for Sanofi, recording a sales growth of 16.7% to €5,782 million, mainly attributed by Lantus. In Q4 2012, diabetes sales increased by 20.9% ...

The company’s partnerships with major players like Sanofi and AstraZeneca highlight its competitive position in the biotech sector. Revenue: CHF 20.1 million in 2024, primarily from ...

The company’s partnerships with major players like Sanofi and AstraZeneca highlight its competitive position in the biotech sector. Revenue: CHF 20.1 million in 2024, primarily from collaboration ...

Novavax recently announced its earnings for Q4 2024, showing a significant improvement ... Additionally, a co-exclusive licensing agreement with Sanofi in May 2024 for its vaccine, with ...